

Sleep Apnea Therapeutic Pipeline Market Review, H2 2016

Sleep Apnea Drugs and Companies Pipeline Review H2 2016

PUNE, INDIA, September 19, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for [Sleep Apnea](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sleep Apnea and features dormant and discontinued projects.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Complete Report @ <https://www.wiseguyreports.com/reports/643477-sleep-apnea-pipeline-review-h2-2016>

Scope

- The report provides a snapshot of the global therapeutic landscape of Sleep Apnea
- The report reviews pipeline therapeutics for Sleep Apnea by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Sleep Apnea therapeutics and enlists all their major and minor projects
- The report assesses Sleep Apnea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type



- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Sleep Apnea

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/643477-sleep-apnea-pipeline-review-h2-2016>

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sleep Apnea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sleep Apnea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Have any query @ <https://www.wiseguyreports.com/enquiry/643477-sleep-apnea-pipeline-review-h2-2016>

Table of Content

Sleep Apnea Overview	6
Therapeutics Development	7
Pipeline Products for Sleep Apnea - Overview	7
Pipeline Products for Sleep Apnea - Comparative Analysis	8
Sleep Apnea - Therapeutics under Development by Companies	9
Sleep Apnea - Therapeutics under Investigation by Universities/Institutes	10
Sleep Apnea - Pipeline Products Glance	11
Late Stage Products	11
Clinical Stage Products	12
Early Stage Products	13
Sleep Apnea - Products under Development by Companies	14
Sleep Apnea - Products under Investigation by Universities/Institutes	15
Sleep Apnea - Companies Involved in Therapeutics Development	16
Galleon Pharmaceuticals	16
RespireRx Pharmaceuticals Inc.	17
SK Biopharmaceuticals Co., Ltd.	18
Vivus, Inc.	19
Sleep Apnea - Therapeutics Assessment	20
Assessment by Monotherapy Products	20
Assessment by Combination Products	21
Assessment by Target	22
Assessment by Mechanism of Action	24
Assessment by Route of Administration	26
Assessment by Molecule Type	27
Drug Profiles	28
(phentermine + topiramate) ER - Drug Profile	28

Product Description 28
Mechanism Of Action 28
R&D Progress 28
CX-1739 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
dronabinol - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
GAL-475 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
GAL-475 Backups - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
SKL-N05 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecule for Sleep Apnea - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Sleep Apnea - Dormant Projects 46

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=643477

Continued...

Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.